Safety of Simvastatin in the Treatment of Patients with Dyslipidemia / 中国药房

ABSTRACT

OBJECTIVE: To explore the safety of different dosages of simvastatin in patients with dyslipidemia. METHODS: 269 patients with essential dyslipidemia were randomly assigned to receive simvastatin (5, 10 or 40 mg?d-1) for 8 weeks. The curative efficacy and the adverse reactions were compared among groups. RESULTS: There were significant differences across the 3 groups (5, 10 or 40 mg?d-1) with regard to the total effective rates on regulating total cholesterol, triglyceride, high-density lipoprotein cholesterol(P0.05). The total incidence of ADRs was 14.87%, which appeared mainly as gastrointestinal reaction and myosalgia, and the differences across the 3 groups were significant (P=0.03), but no significant difference was noted with regard to sex and age (P=0.46,P=0.07). CONCLUSION: Simvastatin may induce ADRs, but in most cases the ADRs were mild,and the incidence of the ADRs increased as the dosage of simvastatin increased.Tailoring the dosage of simvastatin to patients’ clinical characteristics is conducive to patients’ medication safety.